Active

Rewiring blood cells that block the immune response with AI

Cancer types:

Lung cancer
General cancer research

Project period:

Research institute:

Vlaams Instituut voor Biotechnologie vzw

Award amount:

£222,243

Location:

Belgium

Peter Carmeliet Headshot
Researcher Professor Peter Carmeliet

Professor Peter Carmeliet and his team are working on what could be a new type of immunotherapy. If successful, their new approach could treat more patients with several cancer types.

Hope for the future

Immunotherapy has been a revolution in cancer therapy, providing many patients with a new hope for treatment and giving them more time with their loved ones. Sadly, immunotherapy does not work for every patient. Researchers around the world are still finding new ways to make immunotherapy work better and give hope to even more patients with cancer.


Professor Carmeliet and his team are hoping to reverse one of the reasons behind immunotherapy’s inconsistent effect. They are going to target a specific cell (blood vessel cells) that normally suppresses the immune system, and try to get it to boost the immune system instead, prompting it fight off the cancer. If successful, this would be a brand-new type of immunotherapy ready for new clinical uses.

Peter Carmeliet Team Shot
Meet the scientist

At the age of 18, Professor Carmeliet had to decide between becoming a professional flutist, engineer, or physician scientist – following his father’s advice (himself a prominent researcher) on the power research holds to change patients’ lives, he decided to study medicine, and the rest is history. As expected for a scientist, Professor Carmeliet likes to explore and experiment – that includes in the kitchen!

The science

Immunotherapy is a type of cancer therapy that works by harnessing the immune system to fight off cancer cells. It has huge potential, but sadly many patients’ cancer resists treatment because the tumour suppresses the immune system around it. A specific type of cell that lines the blood supply to a tumour, called an endothelial cell, may be to blame for this immunosuppression.


Professor Carmeliet and his team are aiming to rewire the endothelial cells so that instead of suppressing the immune system they activate it, as a new form of immunotherapy. The researchers will use artificial intelligence (AI) to help them find the best genes to target with the new treatment. They will then check to see what other tissues might be affected by this approach, to make sure there are no other undesired side effects.

These are exciting times, with promising Artificial Intelligence based strategies knocking on the door, a whole new way of performing research! The chance to make an impact, discovering and finding new biological insights and innovative solutions, is what drives me and my team to continue doing what we do.

Peter Carmeliet Headshot
Professor Peter Carmeliet

Related projects

Andres Hidalgo Headshot

Active Spain

Lung cancer

How do cancer cells modify white blood cells to help tumours grow?

Researchers want to help immunotherapy work for more cancer patients by understanding how cancers hijack our immune system and preventing this happening 

Researcher: Dr Andrés Hidalgo

Understanding how cancer cells modify white blood cells to help tumours grow
Andrew Beekman and Team

Active United Kingdom

General cancer research

Can we stop cancer becoming resistant to chemotherapy?

Chemotherapy can sometimes stop working, so this project is hoping to better understand why and find ways to give more, better options to cancer patients.

Researcher: Dr Andrew Beekman

Stopping cancer becoming resistant to chemotherapy
Tim Elliott and Team

Active United Kingdom

General cancer research

Can we predict which patients will respond to immunotherapy?

This project hopes to open up exciting possibilities for personalised cancer treatment by finding how to predict which patients will respond best to treatment.

Researcher: Professor Tim Elliott

Finding ways to predict which patients will respond to immunotherapy
Share this page